BCL2L1 and hepatocellular carcinoma: One of the reasons for the lack of efficacy when performing such a combination is that HCC behaves in a “BCL-xL-dependent tumor,” according to Tutusaus et al. In fact, testing such combination might be of most important because it may overcome sorafenib resistance.